Real-World HbA1c Following Initiation of the Omnipod 5 Automated Insulin Delivery System

作者：Carol J. Levy, D Carlow, Dan J. Swift, Rana Rittgers-Simonds, Noelle N. Gronroos, Valery Walker, Erin Buysman, Gregory P. Forlenza · 发表于：Diabetes Technology & Therapeutics · 年份：2025 · DOI：10.1177/15209156251395014 · 被引用次数：2 · 研究领域：Diabetes Management and Research、Hyperglycemia and glycemic control in critically ill and hospitalized patients、Mobile Health and mHealth Applications

Introduction: The Omnipod® 5 Automated Insulin Delivery (AID) System is the first wearable, on-body, tubeless AID system in the United States. Clinical trials have demonstrated hemoglobin A1C (HbA1c) improvements with Omnipod 5 use. The aim of the study was to evaluate HbA1c changes after initiating Omnipod 5 in a real-world setting. Methods: This retrospective study utilized commercial and Medicare Advantage with Part D enrollees’ claims data from the Optum Research Database between August 1, 2021, and December 31, 2023. The study included individuals diagnosed with type 1 diabetes (T1D) or type 2 diabetes (T2D) who initiated Omnipod 5. Participants were required to have continuous enrollment for 12 months pre- and post-initiation and at least two medical claims for diabetes during these periods. Demographic and clinical characteristics were measured at the index date, and HbA1c levels were compared pre- and post-initiation of Omnipod 5. Results: The final sample included 2,504 users, with 792 having pre- and post-initiation HbA1c results. The mean age was 54 years; 48% were enrolled in Medicare Advantage, 90% had prior continuous glucose monitoring, and 64% had prior pump therapy. A mean reduction in HbA1c of 0.4% was observed ( P < 0.001); mean reductions were 0.4% and 0.5% among those with type 1 and type 2 diabetes, respectively. Among 135 users with pre-initiation HbA1c levels ≥9%, a reduction of 1.4% was noted ( P < 0.001). Pre-initiation, 31% achieved the Americ...